Brand and Other Names:Entereg
Dosing & Uses
Dosage Forms & Strengths
GI Recovery Post Bowel Resection
Indicated to accelerate time to upper and lower GI recovery following surgeries that include partial bowel resection with primary anastomosis
12 mg PO administered 30 minutes to 5 hours preoperative, THEN 12 mg PO q12hr beginning 1 day after surgery until discharge for a maximum of 7 days; patients should not receive >15 doses
Mild to severe impaiment: No dose adjustment necessary; use caution
Mild to moderate impairment: No dose adjustment necessary
Severe impairment: Use not recommended
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Back pain (3.4%)
Black Box Warnings
Increased incidence of myocardial infarction was seen in a clinical trial of patients taking alvimopan for long-term use
Alvimopan is available only for short-term use (not to exceed 15 doses) in hospitalized patients
Only hospitals that have registered in and met all of the requirements for the Entereg (alvimopan) Access Support and Education (E.A.S.E) program may use this drug
Contact: 1-866-4ADOLOR (1-866-423-6567)
Taken >7 day of therapeutic opioids prior to taking alvimopan
Higher risk for MI observed in studies with long-term use (eg, chronic noncancer pain); not observed with postsurgical short-term use
Not recommended in severe hepatic impairment (10-fold higher serum levels), ESRD, bowel obstruction corrective surgery
Not studied in patients having pancreatic or gastric anastomosis; therefore, not recommended for use in these patients
Patients recently exposed to opioids are expected to be more sensitive to the effects of mu-opioid receptor antagonists, symptoms may include abdominal pain, nausea, vomiting, and diarrhea (see Contraindications)
High-fat meal reduces absorption
Available on through a restricted access program (see Black Box Warnings)
Pregnancy & Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Peripheral mu-opioid receptor antagonist; limited ability to cross blood brain barrier so doesn't abolish opioid-induced analgesia nor cause withdrawal symptoms but decreases opioid-induced constipation
Peak Plasma Time: 2 hr
Vd: 20-40 L
Protein Bound: drug 80%; metabolite 94%
Total Clearance: 402 mL/min
Half-Life, Terminal: 10-17 hr
Metabolism: Not by liver, gut microflora hydrolyzes to a metabolite
Excretion: Feces (via biliary excretion) & urine (35%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs